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bstractAnaplastic large cell lymphoma (ALCL), anaplastic lymphoma kinase (ALK)-negative (ALCL-ALK−) is a provisional entity in the WHO
008 Classification that represents 2–3% of NHL and 12% of T-cell NHL. No particular risk factor has been clearly identified for ALCL, but
recent study showed an odds ratio of 18 for ALCL associated with breast implants. Usually, the architecture of involved organs is eroded
y solid, cohesive sheets of neoplastic cells, with peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS) and classical Hodgkin
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bsent, TCR genes are clonally rearranged. CGH and GEP studies suggest a tendency of ALCL-ALK− to differ both from PTCL-NOS and
rom ALCL-ALK+.
Patients with ALCL-ALK− are usually adults with a median age of 54–61 years, and a male-to-female ratio of 0.9. At presentation,
LCL-ALK− is often in III–IV stage, with B symptoms, high International Prognostic Index score, high lactate dehydrogenase serum levels,
nd an aggressive course. ALCL-ALK− presents with lymph node involvement in ∼50% of cases; extranodal spread (20%) is less common.
taging work-up for ALCL-ALK− is similar to that routinely used for nodal NHL. Overall prognosis is poor, with a 5-year OS of 30–49%,
hich is significantly worse when compared to OS reported in patients with ALCL-ALK+ (5-year: 70–86%). Patients with systemic ALCL
xhibit a significantly better survival compared with patients with PTCL-NOS, with a 5-year OS of 51% and 32%, respectively. Age, PIT
coring system, 2-microglobulin, and bone marrow infiltration are the main prognostic factors. The expression of proteins involved in the
egulation of apoptosis (caspase 3, Bcl-2, PI9) and of CD56 is related to clinical outcome.
ALCL-ALK− is generally responsive to doxorubicin-containing chemotherapy, but relapses are frequent. CHOP is the most commonly used
egimen to treat systemic ALCL with complete remission rates of 56%, and a 10-year DFS of 28%. Encouraging results have been reported
ith more intensive chemotherapy regimens. The addition of etoposide improved outcome. Alemtuxumab-CHOP regimen was associated
ith excellent remission rate but increased toxicity. The role of high-dose chemotherapy supported by ASCT has not been investigated in a
rial of exclusively ALCL patients. When used in first remission, it was associated with a 5-year PFS of 64%. High-dose chemotherapy with
SCT is the standard therapeutic option for patients with relapsed or refractory disease. The role of allogeneic transplantation in patients
ith relapsed/refractory ALCL remains to be defined but there are data to support the contention that a graft-versus-lymphoma effect does
xist. Myeloablative conditioning has been associated with 5-year PFS and OS of 40% and 41%, respectively, but a 5-year TRM of 33% was
eported. Allo-SCT can be an option for relapsed/refractory ALCL in younger patients, preferably in the setting of a clinical trial.
Pralatrexate, anti-CD30 monoclonal antibodies, brentuximab vedotin (SGN-35) in particular, 131I-anti-CD45 radioantibody, yttrium-anti-
D25 radioimmunoconjugates, histone deacetylase inhibitors, bortezomib, gemcitabine, vorinostat, lenalidomide, and their combinations
epresent the most appealing chemotherapy and/or targeted agents to be investigated in future trials.
2012 Elsevier Ireland Ltd.
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. General information
.1. Deﬁnition and incidence
In the new WHO Classification, anaplastic large cell
ymphoma (ALCL), anaplastic lymphoma kinase (ALK)-
egative (ALCL-ALK−) is included as a provisional entity.
t is defined as a CD30+ peripheral T-cell neoplasm that is
ot reproducibly distinguishable on morphological grounds
rom ALCL-ALK+, but lacks the ALK protein. Most cases
xpress T-cell-associated markers and cytotoxic markers.
LCL-ALK−must be distinguished from primary cutaneous
LCL, other subtypes of CD30+ T or B-cell lymphoma with
naplastic features, and classical Hodgkin lymphoma.
ALCL, systemic type, represents 2–3% of NHL and 12%
f T-cell NHL. Among all systemic ALCLs, those that are
LK-negative constitute 15–50% of cases. It affects adults
ith a slight predominance in males. The median age at diag-
osis is approximately 55–60 years [1–3]. It usually involves
ymph nodes at diagnosis (49% of cases) and, less frequently,
xtranodal sites (20% of cases). Two-third of patients present
ith stage III–IV of disease and B symptoms.
.2. Risk factors
No particular risk factor has been clearly identified for
LCL. Presently, there is no convincing evidence that virusesausing NHL in humans, such as Epstein–Barr virus (EBV),
he human T-cell leukaemia/lymphoma virus family, or oth-
rs, could be involved in the origin of ALCL. A recent
eries of 64 ALCL cases revealed no EBV-encoded RNA
o
l
ologous transplant; Allogeneic transplant
EBER) or immunohistochemical evidence of EBV-latent
embrane protein type 1 [4]. Correlation between ALCL
nd inherited immunological deficiency disease, or other
mmunological disorders, has not been well documented.
ecent studies showed that autoimmune disorders may con-
ribute to the risk of T-cell ALCL development [5]. Coeliac
isease (odds ratio, 24.0; 95% CI, 8.8–65) and psoriasis (odds
atio, 2.25; 95% CI, 1.00–5.06) have been associated with
ncreased risk of systemic T-cell ALCL, suggesting a possible
athogenic mechanism of chronic antigenic stimulation with
ocal antigenic drive, ultimately leading to the development
f lymphoma.
Although specific studies have not been undertaken in
LCL patients, all histotypes of NHL have been described
s occurring in people whose work involves application
f solvents, pesticides and fertilizers [6–9]. Association of
LCL-ALK− with other malignancies has been anecdotally
eported. Recently, a case of lymphomatoid papulosis fol-
owed by ALCL-ALK+ which then evolved to secondary
LCL-ALK− was reported [10].
A recent study showed an odds ratio of 18.2 (95% CI:
.1–156.8) for ALCL associated with breast implants [11].
n immunologic response (direct or indirect) related to the
rosthesis, direct toxic damage from the silicone compo-
ents, or both mechanisms have been hypothesized, but these
bservations have not been confirmed in formal epidemio-
ogical studies [12]. Although this association remains rare,
00 incidental cases have been reported [13]. Forty cases
f breast implant-associated primary breast anaplastic T-cell
ymphomas have been identified in relation to a specific type
f textured breast prosthesis [14]. A model cell line, T-cell
2 in Oncology/Hematology 85 (2013) 206–215
l
t
o
t
H
I
d
s
A
o
2
2
s
n
i
a
s
T
t
n
p
N
2
A
l
P
e
n
t
c
i
r
a
A
u
e
P
E
2
T
i
m
T
d
Table 1
Clinical features of ALK+ and ALK− ALCL.
ALK-positive ALK-negative
Age at diagnosis 25–35 y 55–60 y
Sex Male predominance Male predominance
Stage at diagnosis III–IV III–IV
B-symptoms Present Present
IPI score High High
Lymph nodes involvement Yes Yes
Extranodal involvement 60% 20%
Extranodal sites Bone, soft tissue,
bone marrow, spleen
Skin, liver, GI tract
Leukaemic phase Rare Rare
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ymphoma breast 1 (TLBR-1) was established from a primary
umour tissue to characterize the phenotype and cytogenetics
f this entity. Staining for CD4, CD8, CD30, EMA were posi-
ive, while ALK-1, keratin, CD2, CD3, CD5CD20, CD56 and
HV-8 was negative. TLBR-1 expressed CD25 and CD122,
L-2 receptors that made the neoplastic growth IL-2 depen-
ent. This cell line represents an important model for further
tudies of this disease and distinguishes this disease entity of
LCL-ALK−, which appears to have better prognosis, from
ther clinical forms.
. Pathology and biology
.1. Morphology
Usually, the organ architecture is erroded by solid, cohe-
ive sheets of neoplastic cells. In the lymph node, the
eoplastic cells tend to be diffuse through sinuses, mimick-
ng metastatic involvement from carcinoma. Features such
s sclerosis or eosinophilia may occur, but when present
hould raise the suspicion of classical Hodgkin lymphoma.
he neoplastic cells show a similar morphological spectrum
o ALCL-ALK+, although a “small cell variant” is not recog-
ized. The main differential diagnoses of ALCL-ALK− are
eripheral T-cell lymphoma-not otherwise specified (PTCL-
OS) and classical Hodgkin lymphoma.
.2. Immunophenotype
With complete immunophenotypic and molecular studies,
LCL-ALK− can be distinguished from classical Hodgkin
ymphoma in virtually all cases. In this regard, staining for
AX5 is useful: classical Hodgkin lymphoma will show weak
xpression of PAX5 in the majority of cases – a finding
ever observed in ALCL-ALK−. By contrast, the distinc-
ion between PTCL-NOS and ALCL-ALK− is not always
lear-cut. In ALCL-ALK−, all tumour cells are strongly pos-
tive for CD30, usually at the cell membrane and in the Golgi
egion. Staining should be strong and of equal intensity in
ll cells, a feature that is important in distinguishing ALCL-
LK− from other PTCLs. By contrast, CD30 staining is
sually more heterogeneous and weak. Loss of T-cell mark-
rs can occur, with greater frequency than typically seen in
TCL-NOS. A substantial minority of cases is positive for
MA.
.3. Genetics
The genetics of T-cell lymphomas are poorly understood.
he only well characterized abnormality is the translocation
nvolving ALK, absent in ALK-negative lymphomas. The
ajority of cases (74–90%) show clonal rearrangement of
CR genes [15,16].
CGH studies indicate a tendency of ALCL-ALK− to
iffer both from PTCL-NOS and from ALCL-ALK+ [17].
A
s
v
pNS involvement Rare Rare
imilarly, gene expression profiling studies suggest that
LCL-ALK− has a distinct profile.
Recurrent IRF4 (interferon regulatory factor-4) translo-
ations were recently found in PTCL-NOS and cutaneous
LCL and may represent a diagnostic tool to distinguish
hese entities from ALK-negative lymphomas which that
acked this translocation [18].
Recently, the translocation t(6;7)(p25.3;q32.3) was
emonstrated in ALK-negative ALCL [18]. The 6p25.3 dis-
upted DUSP22, a dual specificity phosphatase that inhibits
-cell antigen receptor signalling in reactive T-cells by inac-
ivating the MAPK, ERK2 [19]. DUSP22 expression has a
umour suppressor function and the translocation resulted in
USP22 deregulation.
. Diagnosis
.1. Clinical presentations
Patients with ALCL-ALK− are usually older than those
ffected by ALK-positive ALCL, with a median age at diag-
osis of 54–61 years, compared with 27 years for the latter
roup; the male-to-female ratio is 0.9, being similar between
LK groups [1–3,20]. The main differences in clinical pre-
entation between ALK-negative and ALK-positive ALCLs
re given in Table 1. At presentation, ALCL-ALK− is often
n III–IV stage, with B symptoms, high International Prog-
ostic Index (IPI) score, high lactate dehydrogenase (LDH)
erum levels, and an aggressive course [20,21].
ALCL-ALK− presents with lymph node involvement in
50% of cases; extranodal spread (20% of cases) is less
ommon than in the ALK-positive form [1,22,23]. The most
requent extranodal sites in ALCL-ALK− are skin, liver and
ung involvement compared with bone and soft tissue in
LCL-ALK+ [2]. Few cases of primary pancreatic localiza-
ion have been reported [24]. Breast lymphomas are mainly
LCL-ALK− [25]. Bone marrow has been reported as aite, although at a lower frequency than PTCL-NOS (7%
s. 21%) [2]; peripheral blood dissemination (as leukaemic
hase) is rare. There are rare reports of ALCL presenting as a
A.J.M. Ferreri et al. / Critical Reviews in Oncology/Hematology 85 (2013) 206–215 209
Table 2
Ann Arbor staging system.
Stage I Involvement of a single lymph node region or single lymphoid structure, such as spleen, thymus or Waldeyer ring (I), or a single
extranodal site (IE).
Stage II Involvement of two or more lymph node regions or lymphoid structures on the same side of the diaphragm (II) or localized
involvement of an extralymphatic site (IIE). The number of anatomical regions involved should be indicated by a subscript (e.g.,
II3). Mediastinal nodes are a single lymph node region.
Stage III Involvement of lymph nodes regions or lymphoid structures on both sides of the diaphragm (III), or localized involvement of an
extralymphatic site (IIIE), or spleen (IIIs) or both (IIIEs). Moreover, stage III1 – characterized by splenic, hilar, coeliac or portal
node involvement – can be distinguished from stage III2 which presents para-aortic, iliac and/or mesenteric node involvement.
Stage IV Diffuse or disseminated involvement of one or more extralymphatic organs with or without associated lymph node involvement.
Localized involvement of liver or bone marrow is also considered stage IV.
Extranodal disease Extranodal categorization in stages I–III includes a single extralymphatic involvement by limited direct extension from an adjacent
nodal site. Extranodal involvement should be identified by a symbol (M: marrow, L: lung, D: skin, H: liver, P: pleura, O: bone).
Systemic symptoms Fever > 38 ◦C of no evident cause for 3 consecutive days, night sweats and unexplained weight loss > 10% of body weight. Patients
are divided according to the presence (B) or not (A) of these symptoms.
Bulky disease Palpable masses and abdominal masses (CT scan or MRI) are defined as “bulky” when its largest dimension is ≥10 cm. Mediastinal
mass is defined as “bulky” on a posteroanterior chest radiograph, when the maximum width is ≥one-third of the internal transverse
diameter of the thorax at the level of T5–T6 vertebrae.
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seukaemic disease, typically in children, when it is associated
ith a worse prognosis [26].
ALCL involvement of the central nervous system (CNS)
s uncommon. Primary CNS ALCL has been reported in 14
ases, similarly distributed between ALK+ and ALK− [27].
n these patients, clinical outcome was worse than in other
ystemic extra-nodal ALCL and mortality was greater than
n other CNS lymphomas. The course was generally rapid
nd fatal due to progressive neurological deterioration.
. Staging
.1. Staging procedures
Complete staging and work-up for ALCL is similar to that
outinely used for nodal NHL. It includes an accurate phys-
cal examination, complete haematological and biochemical
xams, total-body computerized tomography, and bone mar-
ow aspirate and biopsy. Under certain circumstances, special
rocedures are required. CNS MRI or CT scan and CSF cytol-
gy examination is indicated in patients with neurological
ymptoms. Although extremely rare, bone lesions should be
onfirmed by routine X-ray studies, and biopsied if possible.
ome particular sites of disease frequently involved by ALCL
equire special diagnostic procedures, such as gastrointestinal
ract radiologic and endoscopic assessment. The staging of
tomach and colon-rectum disease requires gastroscopy with
everal biopsy samples of macroscopically evident lesions,
hile the small intestine should be studied with contrasted
adiological techniques. Ultrasonography and MRI are useful
or investigating the involvement of breast, soft tissue, sali-
ary glands or orbits. Surgical procedures such as laparotomy
r laparoscopy with multiple liver biopsies and splenectomy
lay a major role in histopathological diagnosis but are not
ncluded as part of the routine staging procedures.
5
2
[.2. Staging system
The standard staging system used for ALCL is the same as
hat proposed for Hodgkin’s disease at the Ann Arbor Con-
erence in 1971 [28]. This system is currently used for all
on-Hodgkin’s lymphomas, even if other staging systems are
sed in some extranodal lymphomas with particular biologi-
al behaviours. The Ann Arbor staging system reflects both
he number of sites of involvement and the presence of disease
bove or below the diaphragm (Table 2). Patients are divided
nto two subsets according to the presence (A) or absence
B) of systemic symptoms. Fever of no evident cause, night
weats and weight loss of more than 10% of body weight are
onsidered systemic symptoms. The presence of bulky mass,
uch as a lesion of 10 cm or more in the longest diameter is
ignalled as “X”, while the extranodal involvement should be
dentified by a symbol (O: bone, L: lung, D: skin, etc.).
. Prognosis
.1. Natural history
Adult patients with ALCL-ALK− generally receive
HOP-like or MACOP-B regimens, while paediatric patients
re usually treated following lymphoblastic leukaemia
rotocols [20]. ALCL-ALK− is generally responsive to
oxorubicin-containing chemotherapy, but relapses are fre-
uent. In the published series, the prognosis of patients with
LCL-ALK− is poor, with a 5-year overall survival (OS)
f 30–49%, versus 70–86% in ALK+ ALCL [2,3,20,29].
atients with systemic ALCL exhibit a significantly better
urvival compared with patients with PTCL-NOS [30], with a
-year progression free survival (PFS) and OS of 39% versus
0% (p = 0.01) and 51% versus 32% (p = 0.02), respectively
2], but not all analyses support this observation [31].
210 A.J.M. Ferreri et al. / Critical Reviews in Onco
Table 3
Prognosis in ALK+ and ALK− ALCL according to reported series after
upfront CHOP-like chemotherapy.
ALK-positive ALK-negative
Gascoyne (1999) 5-y OS 93% 5-y OS 37%
5-y PFS 88% 5-y PFS 37%
Savage (2008) 5-y OS 70% 5-y OS 49%
5-y FFS 60% 5-y FFS 36%
Falini (1999) ORR 92% ORR 84%
10-y DFS 82% 10-y DFS 28%
Schmitz (2010) 3-y OS 89% 3-y OS 62%
3-y EFS 76% 3-y EFS 46%
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9.4% (n = 67) had systemic ALCL, but ALK status was
not defined in the original publication [36]. The addition.2. Prognostic factors
The impact of NPM-ALK expression on patient out-
ome was first observed in a series of 105 cases of adult
LCL, including T-cell and null-cell phenotypes [32]. In
nother series, stratification of ALCL according to ALK
xpression demonstrated a significantly favourable progno-
is for patients with ALK-positive ALCL, with a 5-year
S of 93% vs. 37% (p < 0.00001) and 5-year PFS of 88%
s. 37% (p < 0.0001) [32] (Table 3). From these and other
eported series, a range of prognoses has been observed with
ore favourable outcomes reported in recent large, compre-
ensive analyses (Table 3). Differences may reflect varying
tringency in pathologic review as well as the proportion
f patients with high-risk disease by the IPI, which also
mpacts survival in both ALK+ and ALK− ALCL [2,18,31].
owever, overall, the observed 5 year failure-free survival
s approximately 35–45% and OS ranges from 30 to 49%.
he latter variability may also be due to variable duration of
ollow-up as well differences in the salvage rate if younger
atients are able to receive high dose chemotherapy and stem
ell transplant at relapse. It is matter of debate whether it is
olely the presence of ALK fusion protein that explains the
ifference in prognosis between ALK− and ALK+ patients.
f the comparison of ALK− and ALK+ patients is confined
o a specific age group (e.g., <40 y), there is no difference
n outcome – suggesting that age is a critical determinant of
rognosis [2,3]. In addition to the IPI, the prognosis in T-
ell lymphoma (PIT) scoring system, which was originally
eveloped for PTCL-NOS patients and incorporates age, per-
ormance status, LDH, and bone marrow involvement [33]
as also been shown to be predictive of PFS and OS in ALCL
2]. A study from the GELTAMO (Spanish Cooperative
roup for Bone Marrow Transplants in Lymphomas) in 123
atients with relapsed/refractory T-cell NHL (31 were ALCL,
5%) showed that at least two among adjusted IPI factors, >1
xtranodal site of disease, and elevated 2-microglobulin at
ime of transplant were associated with inferior survival [34].
In the GELA trials, in addition to age <40 y, -2
icroglobulin was prognostic for OS in multivariate analysis
oth in ALCL-ALK+ and ALCL-ALK−; liver involvement,
o
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lbumin level and IPI were prognostic factors in ALCL-
LK− [35].
The expression of proteins involved in the regulation of
poptosis, such as activated caspase 3, Bcl-2 and PI9, is
elated to clinical outcome [31]. The expression of CD56, a
eural cell adhesion molecule, predicted a poor prognosis in
series of 143 patients with ALK± ALCL, with a 5-year OS
f 28% vs. 65% (p = 0.002), respectively for CD56-positive
nd CD56-negative ALCL [31]. Bone marrow infiltration
eems to be associated with worse prognosis, regardless of
he ALK-expression [37].
. Treatment
.1. Treatment of primary ALCL-ALK−
The optimal therapy for ALCL-ALK− is controver-
ial due to: the rarity of this disease, the heterogeneity
f clinical presentation, and the lack of randomized trials
ocused on this lymphoma. ALCL-ALK− is usually ana-
ysed together with other T-cell lymphomas and patients are
nrolled in prospective trials designed to include most periph-
ral T-cell lymphoma categories. Series focused exclusively
n adult patients with ALCL are small and retrospec-
ive.
Chemotherapy for peripheral T-cell lymphomas has been
erived from experiences in aggressive B-cell lymphoma.
HOP (cyclophosphamide, doxorubicin, vincristine, pred-
isone) is the most commonly used regimen to treat
ystemic ALCL. In a retrospective series, ALCL-ALK−
atients treated with second- and third-generation chemother-
py regimens showed an ORR and complete remission
ates (CRR) of 84% and 56%, respectively, with a 10-
ear disease-free survival (DFS) of 28% suggesting that
ore dose intensive regimens did not impact outcome
38]. Encouraging results have been reported with ACVBP
hemotherapy (doxorubicin, cyclophosphamide, vindesine,
leomycin, prednisone) followed by a consolidation therapy
ith high-dose methotrexate, ifosfamide, etoposide, asparag-
nase, and cytosine-arabinoside or m-BACOD (methotrexate,
leomycin, Adriamycin, cyclophosphamide, vincristine,
examethasone), VIMMM (VM26, ifosfamide, mitox-
ntrone, methyl-gag, methotrexate)/ACVBP, and CHOP
36]. Patients with T-cell ALCL had a CR rate of 69%
nd a 5-year OS of 63%, however, patients were not strat-
fied by ALK expression; 75% were <60 years of age and
0% had stage I or II disease. The NHL-B1 trial added
toposide to CHOP and reduced the treatment interval from
1 to 14 days in young patients with aggressive NHL and
ood prognostic markers. In this trial, 710 patients were
nrolled; 14% of patients had peripheral T-cell lymphoma;f etoposide improved CR from 79% to 88% and 5-year
FS by 12%; CHOEP-14 resulted in an increased OS;
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Table 4
Therapeutic results of published studies containing patients with ALCL-ALK−.
Paper (year of publication) No. FFS/EFS/PFS OS Comment
Shiota (1995) 75 Not reported 5 y: 33% Retrospective study Treatment not detailed
Gascoyne (1999) 26 5 y: 37% 5 y: 37% Retrospective study
ten Berge (2003) 44 ∼5 y: 40%a 5 y: 40% Retrospective study
Savage (2008) 72 5 y: 36% 5 y: 49% International PTCL project retrospective study
Schmitz (2010) 113 3 y: 46% 3 y: 62% Retrospective study of PTCL patients enrolled in German high grade studies
Sibon (2010 abstract) 74 8 y: 39% 8 y: 49% Retrospective study of 3 GELA studies
No.: Number of pts with ALCL-ALK−.
a Estimate from PFS curve.
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sowever, the subgroup of ALCL was too small to draw reli-
ble conclusions. In the NHL-B2 study, among 689 patients,
% had T-cell histology including 23 cases of ALCL (3.5%).
n a multivariate analysis, CHOP-14 was associated with
mproved EFS and OS compared to CHOP-21 in aggres-
ive lymphomas, but there were limited number of patients
ith T-cell lymphoma [37]. More recently the German high
rade aggressive NHL study compiled a retrospective series
f 320 patients with peripheral T-cell lymphoma from 7
hase II and III trials, including NHL-B1 and NHL-B2
39]. In total, there were 191 patients with ALCL including
13 cases of ALCL-ALK− treated with CHOP (CHOP-14,
HOP-21), CHOEP (CHOP-14/21 plus etoposide) or inten-
ified CHOEP (High-CHOEP14/21 or Mega-CHOEP). The
-year EFS and OS were 46% and 62%, respectively, in
atients with ALCL-ALK− (Table 4). In younger patients
ith a normal LDH an improved EFS, but not OS, was
bserved. However, there was only a trend to improved EFS
p = 0.057) when patients with ALK+ ALCL were excluded.
he analysis was not exclusively confined to patients with
LK-ALCL.
An Italian trial has analysed the role 4–8 cycles
f an alemtuxumab-CHOP regimen (combination of the
nti-CD52 monoclonal antibody alemtuzumab and CHOP
hemotherapy) in 24 patients with PTCL, including three
ith ALCL-ALK−. Alemtuzumab has been administered
n day 1 of each cycle at dose of 30 mg subcutaneously and
atients were treated on a Q28 day schedule. All patients with
LCL-ALK− achieved a CR and were still alive at time of
nalysis. Median duration of response was 11 months. Major
bserved toxicities were infections (aspergillosis, staphylo-
occus sepsis, bacterial pneumonia and Jacob-Creutzfeldt
iral encephalitis) [40].
The role of high-dose chemotherapy supported by autol-
gous stem cell transplant (ASCT) has not been investigated
n a trial of exclusively ALCL patients. Patients with ALCL-
LK− are usually treated in the same way as and analysed
ogether with all other aggressive T-cell lymphomas, whereas
atients with ALCL-ALK+ are usually excluded. An excep-
ion was a retrospective series of 62 PTCL patients with
tage II–IV disease, among which there were 19 ALK-
ositive ALCLs and four ALCL-ALK−, who were treated
b
i
Aith debulking chemotherapy, followed by intensified treat-
ent and ASCT. The associated 12-year OS, DFS and EFS
ere 34%, 55% and 30%, respectively [41]
One hundred and thirty-eight patients with ALCL (64
LK+ and 74 ALK−) were retrospectively reviewed from
he LNH87–LNH93–LNH98 GELA prospective trials and
ere analysed to address the role of high-dose chemotherapy
upported by ASCT in aggressive lymphomas. All but one
atient received an anthracycline-based regimen; 22 ALCL
atients (16 ALK+ and 6 ALK−) underwent upfront HDT-
SCT. The ORR was 76% in ALCL-ALK− subgroup, with
n OS of 49% at a median follow-up of 8 years [35]. In
his study, patients who were transplanted had an improved
year OS, however only 6 patients with ALCL-ALK− were
ncluded. Bone marrow involvement, more than one extran-
dal site, liver involvement, albumin level, and IPI all were
dverse prognostic factors [35,42].
The role of ASCT in patients with ALCL in first remis-
ion has been investigated in some small studies (n = 16–40),
ith 5-year OS rates of up to 80%, however, in many of
hese studies, ALK expression was not assessed, and lym-
homas with B, T and null Immunophenotype were included
43,44]. Treatment with four to six courses of dose-escalated
HOP plus etoposide followed by ASCT has been associ-
ted with a disappointing 3-year EFS and OS of 26% and
5%, respectively, for the whole group of patients with T-
ell lymphoma [45]. The Nordic group has completed the
argest prospective phase II trial of upfront transplant in
60 patients with PTCL, excluding ALCL-ALK+. The sub-
roup of patients with ALCL-ALK− was analysed separately
n = 31) and had an encouraging 5 year PFS (64%) which was
uperior to either PTCL-NOS or AILT. Unfortunately, there
re no prospective phase III trials assessing the question of
hether to transplant patients upfront, at first remission, or
o keep transplant for relapsed disease, conducted in series
xclusively comprised of patients with ALCL. Prospective
andomized studies comparing conventional chemotherapy
ith HDC/ASCT are needed before ASCT may be con-
idered standard therapy. Examination of high-risk patients
y IPI and/or molecularly based prognoses may help to
dentify patient groups that will benefit from consolidative
SCT.
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.2. Treatment of relapsed or refractory disease
The standard therapeutic option for patients with relapsed
r refractory disease has not been established. Treatment
ith gemcitabine, cisplatin and methylprednisolone has been
ndertaken in 16 patients with relapsed PTCL, two of
hom had ALCL-ALK−; both patients achieved a partial
esponse, which lasted 3 and 14 months, respectively [46].
everal retrospective studies support the finding that high-
ose chemotherapy with ASCT (HDC/ASCT) can salvage
atients with relapsed ALCL [35,47–50]; however, these
ere retrospective studies focused on patients with different
elapsed/refractory T-cell lymphomas, including a variable
roportion of patients with ALCL, where often ALK sta-
us was not specified. Some studies showed an association
etween ALCL category and better outcome [49,50], while
thers did not show this difference [35]; this discrepancy
ould be explained by an unbalanced distribution of ALCL-
LK+ cases among studies.
The role of allogeneic transplantation in patients with
elapsed/refractory ALCL remains to be defined but there
re data to support the contention that a graft-versus-
ymphoma effect does exist. An older study on patients with
elapsed/refractory aggressive NHL treated with myeloab-
ative conditioning showed comparable outcomes among
-cell and T-cell lymphoma, with 5-year PFS and OS of 40%
nd 41% for the whole series [51]. In a recent retrospective
nalysis of 77 T-cell lymphomas treated with myeloabla-
ive conditioning and allo-SCT after at least one previous
reatment line (ALCL = 35%) [52], the 5-year EFS and OS
or ALCL patients were 48% and 55%, respectively. This
as similar to that observed in the other T-cell lymphomas
here a 5-year treatment-related mortality of 33% was
eported. ALK status did not impact survival. Patients with
hemorefractory lymphoma have benefited from allo-SCT,
ith 5-year OS of 29%. A study of chemotherapy followed
y allo-SCT with reduced-intensity conditioning and planned
onor lymphocyte infusions was conducted in 17 patients
ith relapsed T-cell NHL (ALCL = 4) [53]. All four ALCL
atients were event-free at a median follow-up of 17 months.
lloSCT can be an option for relapsed/refractory ALCL
n younger patients, preferably in the setting of a clinical
rial.
.3. New drugs or experimental approaches
Pralatrexate, a novel antifolate methotrexate analogue,
as shown higher affinity for the reduced folate carrier
ype 1 (RFC-1) and increased intracellular uptake than
ethotrexate. The maximum tolerated dose is 30 mg/m2
eekly for 6 weeks every 7 weeks [54]. Among 57 patients
ith B- and T-cell lymphomas, ORR was 60%. Two
atients with ALCL (one ALK−) achieved CR; response
as longer in the ALCL-ALK+ patient (48 months vs. 8
onths).
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CD30 is a promising therapeutic target. After an initial
hase where several anti-CD30 antibodies showed consid-
rable in vitro activity (i.e., the human IgG1k antibody
DX-060, the human antibody 5F11, the humanized anti-
ody XmAb 2513, the chimeric antibody SGN-30, the
mmunotoxin ki-4dgA), but modest clinical activity in
atients with CD30-positive lymphomas (i.e., Hodgkin lym-
homa and ALCL) [55–57], recently reported studies showed
elevant clinical activity with some interesting molecules.
oteworthy, an anti-CD30 antibody–drug conjugate was
eveloped: brentuximab vedotin (SGN-35). This promising
gent is a conjugate constituted by the antitubulin agent
onomethyl auristatin E and a CD30-specific monoclonal
ntibody that has shown excellent activity both in Hodgkin
ymphoma and ALCL. In preclinical mouse xenograft mod-
ls it induced durable responses, showing significant clinical
ctivity in relapsed systemic ALCL [58]. Recently, a phase
I multicentre study evaluated activity and safety in 58
atients with relapsed or refractory ALCL (72% of cases
ere ALK-negative); the ORR was 86%, with a CRR of
3% [59]. The response rate was comparable in ALK+
nd ALK− patients and the median duration of response
ad not yet been reached at the time of the analysis.
bserved toxicities were peripheral sensory neuropathy, nau-
ea, fatigue and diarrhoea. A study combining CHOP and
rentuximab in the primary therapy of systemic ALCL is
nderway.
Radioimmunoconjugates have potential therapeutic value
n T-cell NHL. A radioimmunoconjugate in preclini-
al development is 131I-anti-CD45 radioantibody [60].
ther radioimmunoconjugates that could be useful are
odine-anti-CD25, yttrium-anti-CD25 and yttrium anti-CD5
61].
Histone deacetylase inhibitors induce chromatin relax-
tion, gene expression of tumour suppressors and cell growth
rrest. Related trials have demonstrated safety and activity in
re-treated cutaneous T-cell lymphomas, but no data specif-
cally in systemic ALCL are available [62].
Because constitutive activation of the nuclear factor
NF)-kappaB has been described in ALCL, single agent
ortezomib has been tested in these malignancies [63]. Com-
inations of bortezomib with gemcitabine or vorinostat are
eing addressed in relapsed/refractory T-cell NHL (including
LCL) in ongoing trials. Synergistic effects between protea-
ome inhibitors and histone deacetylase inhibitors have been
hown in preclinical studies [64].
In preliminary analyses, single-agent lenalidomide also
isplayed activity in relapsed/refractory T-cell NHL, includ-
ng ALCL (ORR 30%) [65]. Continued research is warranted
o predict the potential responses of tumours to novel
hemotherapy and/or targeted agents.onﬂict of interest statement
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